Experimental Treatments for Terminal Conditions and Life-threatening Rare Diseases

Summary

The bill would let licensed physicians prescribe, and qualified hospitals administer, experimental treatments that have passed Phase 1 but are not yet FDA‑approved, to patients with terminal illnesses or life‑threatening rare diseases who have exhausted other options. It requires written informed consent, IRB oversight, a state‑run patient registry, and mandates insurance coverage while setting reimbursement and temporary pricing rules. The measure failed to pass and died in the Health Policy committee.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Topics

Share